Trade Report: The Zacks Investment Research Upgrades Intellia Therapeutics Inc (NTLA) to Hold

The Zacks Investment Research Upgrades Intellia Therapeutics Inc (NTLA) to Hold

Intellia Therapeutics Inc (NASDAQ:NTLA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

NTLA has been the subject of several other research reports. Wedbush reiterated an “outperform” rating and issued a $38.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, August 23rd. Jefferies Group reiterated a “buy” rating and issued a $33.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, August 17th. Leerink Swann upgraded shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $32.00 price target for the company in a research report on Friday, August 5th. Finally, Janney Montgomery Scott assumed coverage on shares of Intellia Therapeutics in a research report on Wednesday, September 28th. They issued a “buy” rating and a $29.00 price target for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $34.20.

Intellia Therapeutics (NASDAQ:NTLA) opened at 15.10 on Thursday. The firm’s 50-day moving average is $19.25 and its 200 day moving average is $21.84. The stock’s market capitalization is $543.52 million. Intellia Therapeutics has a 12-month low of $14.88 and a 12-month high of $30.40.

A number of institutional investors have recently made changes to their positions in the stock. GLG Partners LP purchased a new position in shares of Intellia Therapeutics during the second quarter valued at about $100,000. Pacad Investment Ltd. purchased a new position in shares of Intellia Therapeutics during the second quarter valued at about $117,000. Metropolitan Life Insurance Co. NY purchased a new position in shares of Intellia Therapeutics during the second quarter valued at about $190,000. Teachers Advisors Inc. purchased a new position in shares of Intellia Therapeutics during the second quarter valued at about $235,000. Finally, Marshall Wace LLP purchased a new position in shares of Intellia Therapeutics during the second quarter valued at about $244,000.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Related posts

Leave a Comment